clofibrate has been researched along with fenofibrate in 109 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 42 (38.53) | 18.7374 |
1990's | 28 (25.69) | 18.2507 |
2000's | 19 (17.43) | 29.6817 |
2010's | 17 (15.60) | 24.3611 |
2020's | 3 (2.75) | 2.80 |
Authors | Studies |
---|---|
Bentzen, CL; Nguyen, LM; Niesor, E | 1 |
Branzoli, U; Carganico, G; Chiari, A; Cozzi, P; Lovisolo, PP; Orsini, G; Pillan, A | 1 |
Ashford, A; Ashton, MJ; Loveless, AH; Riddell, D; Salmon, J; Stevenson, GV | 1 |
Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
Henke, BR | 1 |
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T | 1 |
Abuo-Rahma, Gel-D; Aly, OM; Idrees, GA; Radwan, MF | 1 |
Chalmers, DK; Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T; Wielens, J | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Fent, K; Popovic, M; Smital, T; Zaja, R | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Kritchevsky, D; Story, JA; Tepper, SA | 1 |
Goldberg, DM; Hahn, SE | 1 |
Andreu, T; Auwerx, J; Staels, B; van Tol, A | 1 |
Dorić, M; Gligora, M | 1 |
Schwandt, P | 1 |
Kłosiewicz-Latoszek, L; Szostak, WB | 1 |
Ceska, R; Kvasilová, M; Procházková, R; Sobra, J | 1 |
Bost, M; Boucherle, A; Calop, J; Rossignol, AM | 1 |
Balonová, T; Bencová, E; Durisová, M; Horáková, M; Nosál, R; Onderová, E; Ujházy, E; Zeljenková, D | 1 |
Dostert, P; Hartmann, R; Oesch, F; Schladt, L; Strolin-Benedetti, M; Timms, C; Wörner, W | 1 |
Fournel, S; Magdalou, J; Pinon, P; Siest, G | 1 |
Krause, BR; Newton, RS | 1 |
Bonnefis, MT; Infante, R; Petit, D; Rey, C | 1 |
Blane, GF | 1 |
Palmer, RH | 1 |
Hunninghake, DB; Peters, JR | 1 |
Ginsberg, HN | 1 |
Grundy, SM; Vega, GL | 1 |
Chescoe, D; Grasso, P; Hinton, RH; Price, SC; Wright, M | 1 |
Brown, WV | 1 |
Attianese, R; La Ferla, A; Mascarella, A; Migneco, G | 1 |
Blane, GF; Bridges, JW; Grasso, P; Hall, DE; Hinton, RH; Mitchell, FE; Price, SC | 1 |
Bakir, R; Chanu, B; Djian, F; Goy-Loeper, J; Rouffy, J | 1 |
Bridges, JW; Hall, DE; Hinton, RH; Mann, A; Mitchell, FE; Price, SC | 1 |
Agar, N; Bousser, MG; Lacombe, C; Mas, JL | 1 |
Bourdeaux, AM; Paris, RM | 1 |
Hamparian, VV; Hughes, JH; Mehl, JK; Witiak, DT | 1 |
Santafé Oroz, J; Segarra Domènech, J | 1 |
Harvengt, C; Heller, F | 1 |
Daubresse, JC | 1 |
Lehmann-Leo, W; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W; Wegscheider, K | 1 |
Borzatta, V; Ciriolo, MR; Cristofari, M; Mavelli, I; Rotilio, G; Stanzani, L | 1 |
Alsasua, MT; Cepeda, L; Gómez, MP | 1 |
Boucherle, A | 1 |
Blane, GF; Pinaroli, F | 1 |
Kritchevsky, D | 1 |
Lutz, WK; Schlatter, C; von Däniken, A | 1 |
Fregnan, GB; Frigerio, L; Porta, R | 1 |
Clouet, E; Paris, R | 1 |
Olsson, AG; Rössner, S | 1 |
Sznajderman, M | 1 |
Barnard, SD; Caldwell, WJ; Lebeau, JE; Molello, JA | 1 |
Calder, D; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W | 1 |
Schilling, A; Schwartzkopff, W | 1 |
Ishigami, M; Loo, Y; Sano, K; Sasaki, M; Shin, M; Umezawa, C; Yamashita, Y | 1 |
Cherkaoui Malki, M; el Kebbaj, MH; Latruffe, N | 1 |
Dujovne, CA; Lozada, A | 1 |
Haas, T; Hilgertová, J; Justová, V; Sindelka, G; Skrha, J | 1 |
Betteridge, L; Chan, P; Gallagher, K; Munro, E; Patel, M; Schachter, M; Sever, P; Wolfe, J | 1 |
Beaune, P; Foliot, A | 1 |
Ceska, R; Justová, V; Jůzová, Z; Kvasilová, M; Procházková, R; Sobra, J; Wilczek, H | 1 |
Auwerx, J; Grimaldi, P; Schoonjans, K; Staels, B | 1 |
Bismuth, J; Bonne, J; Gharbi-Chihi, J; Teboul, M; Torresani, J | 1 |
Accatino, L; Amigo, L; Andrade, L; Chianale, J; Gonzalez, S; Nervi, F; Pizarro, M; Rigotti, A; Vollrath, V; Wielandt, AM | 1 |
Auwerx, J; Fruchart, JC; Staels, B; Van Tol, A | 1 |
Auerbach, BJ; Barnett, BC; DeMattos, RB; Essenburg, AD; Haubenwallner, S; Krause, BR; Leff, T; Minton, LL; Newton, RS; Pape, ME | 1 |
Diemer, S; Eberlein-König, B; Przybilla, B | 1 |
Bambauer, R; Müller, UA; Schiel, R | 1 |
Farmer, JA; Gotto, AM | 1 |
Alonso-Galicia, M; Roman, RJ; Wilson, TW | 1 |
Miller, DB; Spence, JD | 1 |
Deyashiki, Y; Hara, A; Ishikura, S; Katagiri, Y; Kato, M; Matsuura, K; Miyabe, Y; Sugiyama, T | 1 |
Kockx, M; Kooistra, T; Princen, HM | 1 |
Alary, J; Costet, P; Debrauwer, L; Dolo, L; Guéraud, F; Paris, A; Pineau, T | 1 |
Derudas, B; Gervois, PP; Gonzalez, FJ; Kockx, M; Kooistra, T; Peters, JM; Poulain, P; Princen, HM; Staels, B | 1 |
Wallace, KB; Zhou, S | 1 |
Berge, RK; Derudas, B; Fruchart, JC; Gervois, P; Guerre-Millo, M; Herbert, JM; Madsen, L; Poulain, P; Raspé, E; Staels, B; Willson, TM; Winegar, DA | 1 |
Idzior-Waluś, B | 1 |
Fujisaki, K; Itoh, Y; Maiguma, T; Makino, K; Oishi, R; Sasaguri, T; Takahashi-Yanaga, F; Teshima, D | 1 |
Maki, KC | 1 |
Cariello, NF; Casey, WM; Colton, HM; Creech, D; Falls, JG; Hamilton, G; Kwanyuen, P; McNeil, E; Ni, H | 1 |
Baldwin, GS; Ford, J; Lachal, S; Shulkes, A | 1 |
Chinetti, G; Fontaine, C; Fruchart, JC; Robillard, R; Staels, B | 1 |
Dragomir, E; Manduteanu, I; Simionescu, M; Tircol, M; Voinea, M | 1 |
Bloomfield, HE | 1 |
Behl, C; Clement, AB; Gamerdinger, M | 1 |
Banks, T; Oyekan, A | 1 |
Calin, M; Dragomir, E; Gan, AM; Koenen, RR; Manduteanu, I; Simionescu, M; Stan, D; Weber, C | 1 |
Kasahara, Y; Koga, S; Miyazaki, M; Nakagawa, I; Patricelli, MP | 1 |
Banfi, C; Brioschi, M; Castiglioni, L; Cimino, M; Gelosa, P; Gianella, A; Nobili, E; Pignieri, A; Sironi, L; Tremoli, E | 1 |
Balendiran, GK; Kotheimer, A; Miller, C; Rath, N; Rath, NP; Zeller, M | 1 |
Abe, S; Hattori, H; Ishizawa, K; Kamiya, M; Kawamura, T; Matsumura, K; Matsushita, T; Miyamoto, L; Nakamoto, A; Nemoto, H; Taoka, C; Tsuchiya, K | 1 |
Henze, E; Müller, GA; Patschan, D; Patschan, S; Scheidemann, R; Schwarze, K | 1 |
Hao, Z; Liu, B; Liu, M; Tao, W; Wang, D | 1 |
Klevay, LM | 1 |
Amagase, Y; Mizukawa, Y; Urushidani, T | 1 |
Chen, Z; Wan, T | 1 |
16 review(s) available for clofibrate and fenofibrate
Article | Year |
---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives.
Topics: Animals; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Drug Evaluation, Preclinical; Fenofibrate; Humans; Propionates; Random Allocation | 1987 |
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation | 1987 |
Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Pentanoic Acids | 1987 |
Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives.
Topics: Anticholesteremic Agents; Apolipoproteins; Clofibrate; Fenofibrate; Humans; Kinetics; Lipoprotein Lipase; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Propionates | 1987 |
Fibric acids: effects on lipids and lipoprotein metabolism.
Topics: Bezafibrate; Bile Acids and Salts; Cholesterol; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Pentanoic Acids; Triglycerides | 1987 |
[Pharmacologic therapy of atherosclerosis (I). Current possibilities].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Gemfibrozil; Glycosaminoglycans; Humans; Ion Exchange Resins; Lipoproteins; Nicotinic Acids; Pentanoic Acids; Probucol | 1983 |
Drug interactions with fibric acids.
Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Drug Interactions; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipids | 1994 |
Choosing the right lipid-regulating agent. A guide to selection.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Niacin; Triglycerides | 1996 |
Clinical pharmacokinetics of fibric acid derivatives (fibrates).
Topics: Anticholesteremic Agents; Clofibrate; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver; Mixed Function Oxygenases; Warfarin | 1998 |
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].
Topics: Cardiovascular Diseases; Clofibrate; Fenofibrate; Hemostasis; Humans; Hyperinsulinism; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Insulin Resistance; Lipids; Metabolic Syndrome; Risk Factors | 2001 |
Fibrates for treatment of the metabolic syndrome.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Metabolic Syndrome; Prevalence | 2004 |
Fibrates.
Topics: Animals; Atherosclerosis; Bezafibrate; Cholesterol; Clofibrate; Endothelium, Vascular; Fenofibrate; Humans; Hypolipidemic Agents; Lipid Metabolism; PPAR alpha | 2005 |
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cause of Death; Cholesterol, HDL; Clofibrate; Coronary Disease; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypertriglyceridemia; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke | 2015 |
6 trial(s) available for clofibrate and fenofibrate
Article | Year |
---|---|
Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives.
Topics: Animals; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Drug Evaluation, Preclinical; Fenofibrate; Humans; Propionates; Random Allocation | 1987 |
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation | 1987 |
Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
Topics: Adult; Apolipoproteins A; Apolipoproteins B; Clofibrate; Clofibric Acid; Drug Evaluation; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Propionates; Time Factors | 1985 |
A comparison of fenofibrate and clofibrate hypolipidemic effects.
Topics: Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Clofibrate; Fenofibrate; Humans; Hyperlipidemias; Middle Aged; Propionates; Triglycerides | 1980 |
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Propionates | 1982 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life | 1995 |
89 other study(ies) available for clofibrate and fenofibrate
Article | Year |
---|---|
gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity.
Topics: Animals; Chemical Phenomena; Chemistry; Cholesterol, HDL; Diphosphonates; Lipoproteins, HDL; Male; Phosphates; Rats; Rats, Inbred Strains; Structure-Activity Relationship | 1987 |
N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins.
Topics: Alcohols; Animals; Cholesterol; Enzyme Induction; Hypercholesterolemia; Hypolipidemic Agents; Imidazoles; In Vitro Techniques; Lipoproteins, HDL; Liver; Male; Microbodies; Microsomes, Liver; Organ Size; Pyrimidines; Rats; Rats, Inbred Strains; Structure-Activity Relationship | 1986 |
Heterocyclic analogues of chlorcyclizine with potent hypolipidemic activity.
Topics: Animals; Body Weight; Chemical Phenomena; Chemistry; Cholesterol, Dietary; Eating; Hypolipidemic Agents; Indicators and Reagents; Male; Piperazine; Rats; Rats, Inbred Strains; Structure-Activity Relationship | 1984 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
Topics: Anilino Naphthalenesulfonates; Animals; Fatty Acid-Binding Proteins; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Fluorescence; Substrate Specificity | 2008 |
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Drug Design; Gemfibrozil; Hypolipidemic Agents; Male; Molecular Structure; Propionates; Rats; Rats, Wistar; Stereoisomerism; Triglycerides | 2009 |
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
Topics: Animals; Binding Sites; Carboxylic Acids; Clofibric Acid; Esters; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Ligands; Liver; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Rats; Spectrometry, Fluorescence; Substrate Specificity; Temperature; Thermodynamics | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
Topics: Animals; Evolution, Molecular; Glycosylation; Gonadal Steroid Hormones; HEK293 Cells; Humans; Ion Transport; Organic Anion Transporters; Protein Multimerization; Zebrafish; Zebrafish Proteins | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
[Restrictions also for other lipid-lowering agents?].
Topics: Clofibrate; Fenofibrate; Germany, West; Legislation, Pharmacy; Patient Compliance | 1979 |
Influence of procetofen on lipid metabolism in normocholesteremic rats.
Topics: Absorption; Animals; Cholesterol; Clofibrate; Feces; Fenofibrate; Lipid Metabolism; Liver; Male; Propionates; Rats; Triglycerides | 1979 |
Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate.
Topics: Apolipoproteins A; Apolipoproteins B; Carcinoma, Hepatocellular; Cell Line; Cholesterol; Cholesterol Esters; Clofibrate; Dose-Response Relationship, Drug; Fenofibrate; Humans; Lipoproteins, HDL; Lipoproteins, VLDL; Liver Neoplasms; Triglycerides; Tumor Cells, Cultured | 1992 |
Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat.
Topics: Animals; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Apolipoproteins E; Clofibrate; Fenofibrate; Gene Expression; Intestinal Mucosa; Intestines; Kinetics; Liver; Male; Rats; Rats, Inbred Strains; RNA, Messenger; Transcription, Genetic | 1992 |
Further possibilities of using aryloxycarbonic acid derivatives in clinical practice.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Connective Tissue Diseases; Fenofibrate; Humans; Lymphocyte Activation; Phytohemagglutinins | 1991 |
Fibrates and triglyceride metabolism.
Topics: Bezafibrate; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Triglycerides | 1991 |
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Probucol | 1991 |
[Etolip and Lipanthyl in the treatment of hyperlipoproteinemia].
Topics: Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Propionates | 1990 |
[Treatment of essential hypercholesterolemia by normolipidemic drugs in children].
Topics: Adolescent; Child; Child, Preschool; Cholestyramine Resin; Clofibrate; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Infant, Newborn; Nicotinic Acids; Sulfur | 1989 |
Teratological study of the hypolipidaemic drugs etofylline clofibrate (VULM) and fenofibrate in Swiss mice.
Topics: Animals; Body Weight; Clofibrate; Female; Fenofibrate; Fetus; Gestational Age; Hypolipidemic Agents; Mice; Organ Size; Pregnancy; Propionates; Teratogens | 1989 |
Concomitant induction of cytosolic but not microsomal epoxide hydrolase with peroxisomal beta-oxidation by various hypolipidemic compounds.
Topics: Animals; Aspirin; Clofibrate; Cytosol; Dose-Response Relationship, Drug; Enzyme Induction; Epoxide Hydrolases; Fatty Alcohols; Fenofibrate; Hepatomegaly; Hypolipidemic Agents; Imidazoles; Liver; Male; Microbodies; Microsomes, Liver; Oxidation-Reduction; Palmitoyl-CoA Hydrolase; Probucol; Rats; Rats, Inbred F344 | 1987 |
Differential induction profile of drug-metabolizing enzymes after treatment with hypolipidaemic agents.
Topics: Animals; Biphenyl Compounds; Body Weight; Butyrophenones; Clofibrate; Clofibric Acid; Cytochrome P-450 Enzyme System; Enzyme Induction; Epoxide Hydrolases; Fenofibrate; gamma-Glutamyltransferase; Glucuronosyltransferase; Hypolipidemic Agents; Lipids; Liver; Male; Rats; Rats, Inbred Strains; Structure-Activity Relationship | 1987 |
Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins E; Bezafibrate; Cholesterol, Dietary; Cholesterol, HDL; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Male; Pentanoic Acids; Rats; Rats, Inbred Strains; Valerates | 1986 |
Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats.
Topics: Animals; Apolipoproteins; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Hyperlipidemias; Lipids; Lipoproteins; Liver; Male; Propionates; Rats; Rats, Inbred Strains | 1988 |
Alterations in the thyroids of rats treated for long periods with di-(2-ethylhexyl) phthalate or with hypolipidaemic agents.
Topics: Animals; Clofibrate; Diethylhexyl Phthalate; Electron Probe Microanalysis; Fenofibrate; Iodine; Lysosomes; Microscopy, Electron; Phthalic Acids; Plasticizers; Propionates; Rats; Thyroid Gland; Time Factors | 1988 |
Potential use of fenofibrate and other fibric acid derivatives in the clinic.
Topics: Clofibrate; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins, LDL; Propionates | 1987 |
[Clofibrate hepatitis. A case report].
Topics: Chemical and Drug Induced Liver Injury; Clofibrate; Female; Fenofibrate; Humans; Middle Aged; Time Factors | 1986 |
Time and dose study on the response of rats to the hypolipidaemic drug fenofibrate.
Topics: Animals; Clofibrate; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Fenofibrate; Hypolipidemic Agents; Kidney; Lipid Metabolism; Liver; Lysosomes; Male; Microbodies; Propionates; Rats; Rats, Inbred Strains; Time Factors | 1986 |
Plasma protein changes in rats treated with hypolipidaemic drugs and with phthalate esters.
Topics: Animals; Blood Proteins; Clofibrate; Diet; Diethylhexyl Phthalate; Fenofibrate; Haptoglobins; Hypolipidemic Agents; Immunoelectrophoresis; Male; Phthalic Acids; Rats; Rats, Inbred Strains; Time Factors | 1985 |
Hyperlipidemic dementia.
Topics: Clofibrate; Dementia; Female; Fenofibrate; Humans; Hyperlipidemias; Middle Aged | 1985 |
[Effect of lipid normalizers (clofibrate and procetofene) on chylomicron metabolism in rats].
Topics: Animals; Chylomicrons; Clofibrate; Diglycerides; Fenofibrate; Lipid Mobilization; Liver; Male; Organ Size; Propionates; Rats; Triglycerides | 1980 |
Antiviral activity of antilipidemic compounds on herpes simplex virus type 1.
Topics: Antiviral Agents; Clofibrate; Fenofibrate; Hypolipidemic Agents; Simplexvirus; Thymidine; Viral Plaque Assay; Virus Replication | 1980 |
Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.
Topics: Adult; Bezafibrate; Cholesterol; Clofibrate; Fenofibrate; Humans; Hypolipidemic Agents; Lipase; Lipolysis; Lipoprotein Lipase; Male; Phosphatidylcholine-Sterol O-Acyltransferase; Probucol; Triglycerides | 1983 |
Decrease of superoxide dismutase and glutathione peroxidase in liver of rats treated with hypolipidemic drugs.
Topics: Animals; Clofibrate; Female; Fenofibrate; Glutathione Peroxidase; Hypolipidemic Agents; Liver; Male; Peroxidases; Rats; Rats, Inbred Strains; Superoxide Dismutase | 1982 |
[Hypolipemic action of various drugs in rats poisoned with Triton WR 1339].
Topics: Animals; Cholesterol; Clofibrate; Fenofibrate; Hypolipidemic Agents; Lipids; Male; Nicotinic Acids; Polyethylene Glycols; Pyridinolcarbamate; Rats | 1982 |
[Fenofibrate: chemical development and differences with clofibrate (author's transl)].
Topics: Animals; Chemical Phenomena; Chemistry; Clofibrate; Fenofibrate; Hypolipidemic Agents; Propionates | 1980 |
[Fenofibrate: animal toxicology in relation to side-effects in man (author's transl)].
Topics: Abnormalities, Drug-Induced; Animals; Biopsy; Clofibrate; Cricetinae; Dogs; Female; Fenofibrate; Humans; Hypolipidemic Agents; Liver; Macaca mulatta; Male; Mice; Mutagens; Pregnancy; Propionates; Rabbits; Rats; Reproduction; Transaminases | 1980 |
[Pharmacology of fenofibrate (author's transl)].
Topics: Animals; Cholesterol; Clofibrate; Dogs; Dose-Response Relationship, Drug; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Kinetics; Propionates; Rats; Triglycerides | 1980 |
Lack of covalent binding to rat liver DNA of the hypolipidemic drugs clofibrate and fenofibrate.
Topics: Animals; Carcinogens; Clofibrate; DNA; Female; Fenofibrate; Liver; Male; Propionates; Protein Binding; Rats | 1981 |
Metabolic disorders associated with hyperlipemia: activity of an extremely potent hypolipemic agent (LR 19731).
Topics: Animals; Cholesterol; Clofibrate; Dioxoles; Dose-Response Relationship, Drug; Female; Fenofibrate; Hyperlipidemias; Lipids; Liver; Male; Mice; Motor Activity; Nicotinic Acids; Organ Size; Rats; Thyroidectomy; Triglycerides | 1981 |
[Triglyceride synthesis and oleic acid catabolism by hepatic microsomes and mitochondria in clofibrate or procetofen-treated rats].
Topics: Animals; Clofibrate; Fenofibrate; Liver; Male; Microsomes, Liver; Mitochondria, Liver; Oleic Acid; Oleic Acids; Propionates; Rats; Rats, Inbred Strains; Triglycerides | 1980 |
Effects of combined procetofene--nicotinic acid therapy in treatment of hypertriglyceridaemia.
Topics: Aged; Cholesterol; Clofibrate; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, VLDL; Male; Middle Aged; Nicotinic Acids; Propionates; Triglycerides | 1980 |
[Effect of phenofibrate on the blood serum lipid level in hyperlipoproteinemias and its comparison with clofibrate].
Topics: Adult; Aged; Cholesterol; Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Male; Middle Aged; Propionates; Triglycerides | 1980 |
[Comparative study of the effects of probucol, fenofibrate and clofibrate on liver ultrastructure in rats (author's transl)].
Topics: Animals; Body Weight; Clofibrate; Fenofibrate; Hypolipidemic Agents; Lipids; Liver; Microbodies; Microscopy, Electron; Phenols; Probucol; Propionates; Rats | 1980 |
The effect of etofibrate retard, bezafibrate and procetofen.
Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Lipoproteins; Male; Middle Aged; Patient Compliance; Propionates; Triglycerides | 1980 |
[Comparative research on etofibrate retard and fenofibrate in hyperlipoproteinemia].
Topics: Aged; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Male; Middle Aged; Propionates; Triglycerides | 1980 |
Effect of feeding clofibrate-containing diet on the hepatic NAD+ level in rats.
Topics: Animals; Clofibrate; Diet; Diethylhexyl Phthalate; Fenofibrate; Hypolipidemic Agents; Liver; Male; Microbodies; NAD; Rats; Rats, Sprague-Dawley | 1995 |
Effect of peroxisomes proliferators and hypolipemic agents on mitochondrial inner membrane linked D-3-hydroxybutyrate dehydrogenase (BDH).
Topics: 2,4-Dichlorophenoxyacetic Acid; Animals; Binding, Competitive; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Hydroxybutyrate Dehydrogenase; Hypolipidemic Agents; In Vitro Techniques; Intracellular Membranes; Male; Microbodies; Mitochondria; Mitochondria, Liver; Phospholipids; Rats; Rats, Wistar; Tetrahymena pyriformis | 1995 |
[Relation between hypertriacylglycerolemia and the action of insulin in type 2 diabetes mellitus].
Topics: Adult; Aged; Clofibrate; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged | 1994 |
Growth inhibition of human vascular smooth muscle cells by fenofibrate: a possible therapy for restenosis.
Topics: Bezafibrate; Cell Division; Cells, Cultured; Clofibrate; Fenofibrate; Gemfibrozil; Graft Occlusion, Vascular; Humans; Muscle, Smooth; Platelet-Derived Growth Factor; Saphenous Vein | 1994 |
Effects of microsomal enzyme inducers on glutathione S-transferase isoenzymes in livers of rats and hamsters.
Topics: Animals; Clofibrate; Cricetinae; Cytochrome P-450 Enzyme System; Cytosol; Enzyme Induction; Fenofibrate; Glutathione Transferase; Isoenzymes; Male; Microsomes, Liver; Nafenopin; Organ Size; Rats; Rats, Sprague-Dawley; Substrate Specificity | 1994 |
[Therapy with fibrates and vitamin D metabolism].
Topics: Adult; Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Vitamin D | 1993 |
Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation.
Topics: Adipose Tissue; Animals; Clofibrate; Coenzyme A Ligases; Diet; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Enzymologic; Glucocorticoids; Heart; Kidney; Liver; Liver Neoplasms, Experimental; Male; Mice; Microbodies; Myocardium; Oxidation-Reduction; Rats; Rats, Wistar; Repressor Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tumor Cells, Cultured | 1993 |
Increase of adipose differentiation by hypolipidemic fibrate drugs in Ob 17 preadipocytes: requirement for thyroid hormones.
Topics: Adipose Tissue; Animals; Bezafibrate; Cell Differentiation; Cell Line; Cell Nucleus; Clofibrate; Fenofibrate; Gene Expression Regulation; Hypolipidemic Agents; Mice; Mice, Obese; Receptors, Thyroid Hormone; Thyroid Hormones; Thyroxine | 1993 |
Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Bezafibrate; Bile; Bile Canaliculi; Clofibrate; Clofibric Acid; DNA Primers; Drug Resistance, Multiple; Fenofibrate; Fibric Acids; Gemfibrozil; Gene Expression; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred Strains; Molecular Sequence Data; Multigene Family; Phospholipids; RNA, Messenger; RNA, Ribosomal, 18S | 1996 |
Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat.
Topics: Actins; Animals; Apolipoproteins; Cholestyramine Resin; Clofibrate; Fenofibrate; Gene Expression Regulation; Hypolipidemic Agents; Intestinal Mucosa; Lipid Metabolism; Lipoproteins, HDL; Liver; Lovastatin; Male; Niacin; Probucol; Rats; Rats, Wistar; Simvastatin | 1996 |
Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
Topics: Animals; Apolipoprotein C-III; Apolipoproteins C; Bezafibrate; Cholesterol; Clofibrate; Fenofibrate; Gemfibrozil; Hypolipidemic Agents; Liver; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Triglycerides | 1995 |
Evaluation of the phototoxic properties of some hypolipidemics in vitro: fenofibrate exhibits a prominent phototoxic potential in the UVA and UVB region.
Topics: Bezafibrate; Clofibrate; Dermatitis, Phototoxic; Drug Evaluation, Preclinical; Fenofibrate; Gemfibrozil; Hemolysis; Humans; Hypolipidemic Agents; In Vitro Techniques; Ultraviolet Rays | 1996 |
Effects of lipid-lowering agents in the Dahl salt-sensitive rat.
Topics: Animals; Blood Pressure; Cholesterol; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Diet, Sodium-Restricted; Enzyme Induction; Female; Fenofibrate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Kidney; Kidney Glomerulus; Male; Mixed Function Oxygenases; Pravastatin; Proteinuria; Rats; Rats, Inbred Strains; Sodium, Dietary; Triglycerides; Weight Gain | 1998 |
Activation of human liver 3alpha-hydroxysteroid dehydrogenase by clofibrate derivatives.
Topics: Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductases; Binding Sites; Clofibrate; Clofibric Acid; Dose-Response Relationship, Drug; Enzyme Activation; Fenofibrate; Humans; Hydrogen-Ion Concentration; Hydroxysteroid Dehydrogenases; Hypolipidemic Agents; Liver | 1998 |
Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Alitretinoin; Animals; Apolipoprotein A-I; Cells, Cultured; Clofibrate; Clofibric Acid; Dimerization; Female; Fenofibrate; Fibric Acids; Fibrinogen; Gemfibrozil; Gene Expression Regulation; Genes, Reporter; Hypolipidemic Agents; Liver; Macaca fascicularis; Male; Peroxisome Proliferators; Plasminogen Activator Inhibitor 1; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Transcription Factors; Transcriptional Activation; Tretinoin | 1998 |
In vivo involvement of cytochrome P450 4A family in the oxidative metabolism of the lipid peroxidation product trans-4-hydroxy-2-nonenal, using PPARalpha-deficient mice.
Topics: Aldehydes; Animals; Chromatography, High Pressure Liquid; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Female; Fenofibrate; Hydroxylation; Hypolipidemic Agents; Lipid Peroxidation; Male; Mass Spectrometry; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbodies; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors | 1999 |
Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha.
Topics: Animals; Cells, Cultured; Clofibrate; Clofibric Acid; DNA-Binding Proteins; Fenofibrate; Fibric Acids; Fibrinogen; Gene Expression Regulation; Hypolipidemic Agents; Kinetics; Liver; Male; Mice; Mice, Knockout; Peroxisome Proliferators; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors; Transcription, Genetic; Triglycerides | 1999 |
The effect of peroxisome proliferators on mitochondrial bioenergetics.
Topics: Animals; Bezafibrate; Calcium; Clofibrate; Clofibric Acid; Diethylhexyl Phthalate; Energy Metabolism; Fenofibrate; Fibric Acids; Gemfibrozil; Intracellular Membranes; Male; Membrane Potentials; Mitochondria, Liver; Mitochondrial Swelling; Oxygen; Permeability; Peroxisome Proliferators; Pyrimidines; Rats; Rats, Sprague-Dawley; Trichloroethylene | 1999 |
Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity.
Topics: Adipose Tissue; Animals; Butyrates; Clofibrate; Fenofibrate; Hypolipidemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Obesity; Phenylurea Compounds; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Embryonal; RNA, Messenger; Simvastatin; Time Factors; Transcription Factors; Tumor Cells, Cultured | 2003 |
Visualization and quantitation of peroxisomes using fluorescent nanocrystals: treatment of rats and monkeys with fibrates and detection in the liver.
Topics: Animals; Clofibrate; Dose-Response Relationship, Drug; Fenofibrate; Fluorescent Antibody Technique; Frozen Sections; Humans; Immunoblotting; Liver; Macaca fascicularis; Male; Membrane Proteins; Microscopy, Electron; Peroxisomes; Quantum Dots; Rats; Rats, Wistar; Species Specificity | 2004 |
PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells.
Topics: Bezafibrate; Cell Proliferation; Clofibrate; Clofibric Acid; Colorectal Neoplasms; Fenofibrate; Fibric Acids; Gastrins; Gemfibrozil; Humans; Hypolipidemic Agents; Ligands; Peroxisome Proliferator-Activated Receptors; Protein Precursors; Pyrimidines; Radioimmunoassay; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2004 |
Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Line; Chemokine CCL2; Clofibrate; Dose-Response Relationship, Drug; Endothelial Cells; Fenofibrate; Gene Expression Regulation; Glucose; Humans; NADPH Oxidases; NF-kappa B; Onium Compounds; Peroxisome Proliferators; PPAR alpha; Proto-Oncogene Proteins c-jun; Reactive Oxygen Species; Tosylphenylalanyl Chloromethyl Ketone; Transcription Factor RelA | 2006 |
The role of fibrates in a statin world.
Topics: Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Peroxisome Proliferator-Activated Receptors | 2006 |
Cholesterol-like effects of selective cyclooxygenase inhibitors and fibrates on cellular membranes and amyloid-beta production.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Celecoxib; Cell Line, Tumor; Cell Membrane; CHO Cells; Cholesterol; Clofibrate; Cricetinae; Cricetulus; Cyclooxygenase Inhibitors; Fenofibrate; Mice; Pyrazoles; Sulfonamides | 2007 |
Peroxisome proliferator-activated receptor alpha activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat.
Topics: Angiotensin II; Animals; Cardiovascular Agents; Clofibrate; Fenofibrate; Hemodynamics; Male; Models, Animal; Nitric Oxide; PPAR alpha; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2 | 2008 |
High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells.
Topics: Cell Adhesion; Cells, Cultured; Chemokine CCL2; Chemokine CX3CL1; Clofibrate; Fenofibrate; Flavonoids; Glucose; Humans; I-kappa B Proteins; Imidazoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Monocytes; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NADPH Oxidases; NF-kappa B; NF-KappaB Inhibitor alpha; p38 Mitogen-Activated Protein Kinases; Phosphorylation; PPAR alpha; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-jun; Pyridines; Reactive Oxygen Species; RNA, Messenger; Signal Transduction; Transcription Factor AP-1; Up-Regulation | 2008 |
Proteomics analysis of cardiac muscle from rats with peroxisomal proliferator-activated receptor alpha (PPARalpha) stimulation.
Topics: Animals; Chromatography, High Pressure Liquid; Clofibrate; Female; Fenofibrate; Heart; Heart Ventricles; Muscle Proteins; Myocardium; Myocytes, Cardiac; PPAR alpha; Proteomics; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2010 |
Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats.
Topics: Animals; Blotting, Western; Brain; Chemokine CCL2; Clofibrate; Disease Models, Animal; Fenofibrate; Hypertension; Inflammation; Interleukin-1beta; Kidney Diseases; Ligands; Male; Oxidative Stress; PPAR alpha; Rats; Rats, Inbred SHR; Stroke; Transforming Growth Factor beta | 2010 |
Biomolecular chemistry of isopropyl fibrates.
Topics: Clofibrate; Drug Design; Fenofibrate; Fibric Acids; Hypolipidemic Agents; Molecular Conformation; Structure-Activity Relationship; Surface Properties | 2012 |
Synthesis of highly water-soluble fibrate derivatives via BGLation.
Topics: Animals; Bezafibrate; Clofibrate; Fenofibrate; Hypolipidemic Agents; Male; Rats; Rats, Sprague-Dawley; Solubility; Triglycerides; Water | 2012 |
Fibrate treatment of eEOCs in murine AKI.
Topics: Acute Kidney Injury; Animals; Apoptosis; Cell Movement; Cell Survival; Cells, Cultured; Clofibrate; Endothelial Cells; Fenofibrate; Hypolipidemic Agents; Male; Mice; Mice, Inbred C57BL; PPAR gamma; Vascular Endothelial Growth Factor A | 2014 |
Cholesterotropic and cuprotropic chemicals.
Topics: Animals; Ascorbic Acid; Calcium; Cholesterol; Clofibrate; Copper; Diet; Fenofibrate; Fructose; Humans | 2020 |
Peroxisome proliferator-activated receptor α agonist-induced histidine decarboxylase gene expression in the rat and mouse liver.
Topics: Animals; Cell Proliferation; Cells, Cultured; Clofibrate; Databases, Genetic; Fenofibrate; Gene Expression; Hepatocytes; Histidine Decarboxylase; Hypertrophy; Liver; Male; Mice; Mice, Inbred C57BL; PPAR alpha; Pyrimidines; Rats; Rats, Sprague-Dawley; Species Specificity | 2020 |
Covalent organic nanospheres modified magnetic nanoparticles for extraction of blood lipid regulators in water samples.
Topics: Clofibrate; Fenofibrate; Lakes; Magnetite Nanoparticles; Nanospheres; Water Pollutants, Chemical | 2021 |